Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 6 of 6 publications.

Krege JH, Gilsenan AW, Komacko JL, Kellier-Steele N. Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning, and other label updates. J Bone Miner Res. 2022 Aug 14;6(9):e10665. doi: 10.1002/jbm4.10665

Gilsenan A, Harris D, Reynolds M, McSorley D, Midkiff K, Jackson L, Muldavin B, Kellier-Steele N, Andrews E. Long-term cancer surveillance: results from the Forteo Patient Registry Surveillance Study. Osteoporos Int. 2020 Nov 5;32(4):645-51. doi: 10.1007/s00198-020-05718-0

Gilsenan A, Midkiff K, Harris D, Kellier-Steele N, McSorley D, Andrews EB. Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study. J Bone Miner Res. 2020 Feb;36(2):244-51. doi: 10.1002/jbmr.4188

Gilsenan A, Harding A, Kellier-Steele N, Harris D, Midkiff K, Andrews E. The Forteo patient registry linkage to multiple state cancer registries: study design and results from the first 8 years. Osteoporos Int. 2018 Oct;29(10):2335-43. doi: 10.1007/s00198-018-4604-8

Andrews EB, Gilsenan AW, Midkiff KD, Harris DH. Comments on Bang et al.: the impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers. Osteoporos Int. 2015 May;26(5):1663-4. doi: 10.1007/s00198-014-3003-z

Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, Masica D. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res. 2012 Dec;27(12):2429-37. doi: 10.1002/jbmr.1768